|
1
|
Chu T, D'Angio GJ, Favara BE, Ladisch S,
Nesbit M and Pritchard J: Histiocytosis syndromes in children.
Lancet. 2:41–42. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chu T and Jaffe R: The normal Langerhans
cell and the LCH cell. Br J Cancer Suppl. 23:S4–S10.
1994.PubMed/NCBI
|
|
3
|
Egeler RM, Favara BE, van Meurs M, Laman
JD and Claassen E: Differential In situ cytokine profiles of
Langerhans-like cells and T cells in Langerhans cell histiocytosis:
Abundant expression of cytokines relevant to disease and treatment.
Blood. 94:4195–4201. 1999.PubMed/NCBI
|
|
4
|
Willman CL, Busque L, Griffith BB, Favara
BE, McClain KL, Duncan MH and Gilliland DG: Langerhans'-cell
histiocytosis (histiocytosis X)-a clonal proliferative disease. N
Engl J Med. 331:154–160. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yu RC, Chu C, Buluwela L and Chu AC:
Clonal proliferation of Langerhans cells in Langerhans cell
histiocytosis. Lancet. 343:767–768. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Salotti JA, Nanduri V, Pearce MS, Parker
L, Lynn R and Windebank KP: Incidence and clinical features of
Langerhans cell histiocytosis in the UK and Ireland. Arch Dis
Child. 94:376–380. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Aricò M, Girschikofsky M, Généreau T,
Klersy C, McClain K, Grois N, Emile JF, Lukina E, De Juli E and
Danesino C: Langerhans cell histiocytosis in adults. Report from
the International Registry of the Histiocyte society. Eur J Cancer.
39:2341–2348. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schmitz L and Favara BE: Nosology and
pathology of Langerhans cell histiocytosis. Hematol Oncol Clin
North Am. 12:221–246. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Alston RD, Tatevossian RG, McNally RJ,
Kelsey A, Birch JM and Eden TO: Incidence and survival of childhood
Langerhans cell histiocytosis in Northwest England from 1954 to
1998. Pediatr Blood Cancer. 48:555–560. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
A multicentre retrospective survey of
Langerhans' cell histiocytosis: 348 cases observed between 1983 and
1993. The French Langerhans' Cell Histiocytosis Study Group. Arch
Dis Child. 75:17–24. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Histiocytosis association (2014) LCH in
children.
|
|
12
|
Howarth DM, Gilchrist GS, Mullan BP,
Wiseman GA, Edmonson JH and Schomberg PJ: Langerhans cell
histiocytosis: Diagnosis, natural history, management, and outcome.
Cancer. 85:2278–2290. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gadner H, Grois N, Pötschger U, Minkov M,
Aricò M, Braier J, Broadbent V, Donadieu J, Henter JI, McCarter R,
et al: Improved outcome in multisystem Langerhans cell
histiocytosis is associated with therapy intensification. Blood.
111:2556–2562. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Allen CE, Li L, Peters TL, Leung HC, Yu A,
Man TK, Gurusiddappa S, Phillips MT, Hicks MJ, Gaikwad A, et al:
Cell-specific gene expression in Langerhans cell histiocytosis
lesions reveals a distinct profile compared with epidermal
Langerhans cells. J Immunol. 184:4557–4567. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sahm F, Capper D, Preusser M, Meyer J,
Stenzinger A, Lasitschka F, Berghoff AS, Habel A, Schneider M,
Kulozik A, et al: BRAFV600E mutant protein is expressed in cells of
variable maturation in Langerhans cell histiocytosis. Blood.
120:e28–e34. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Stoecklein NH, Hosch SB, Bezler M, Stern
F, Hartmann CH, Vay C, Siegmund A, Scheunemann P, Schurr P, Knoefel
WT, et al: Direct genetic analysis of single disseminated cancer
cells for prediction of outcome and therapy selection in esophageal
cancer. Cancer Cell. 13:441–453. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Badalian-Very G, Vergilio JA, Degar BA,
MacConaill LE, Brandner B, Calicchio ML, Kuo FC, Ligon AH,
Stevenson KE, Kehoe SM, et al: Recurrent BRAF mutations in
Langerhans cell histiocytosis. Blood. 116:1919–1923. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Satoh T, Smith A, Sarde A, Lu HC, Mian S,
Trouillet C, Mufti G, Emile JF, Fraternali F, Donadieu J and
Geissmann F: B-RAF mutant alleles associated with Langerhans cell
histiocytosis, a granulomatous pediatric disease. PLoS One.
7:e338912012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Go H, Jeon YK, Huh J, Choi SJ, Choi YD,
Cha HJ, Kim HJ, Park G, Min S and Kim JE: Frequent detection of
BRAF (V600E) mutations in histiocytic and dendritic cell neoplasms.
Histopathology. 65:261–272. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bates SV, Lakshmanan A, Green AL, Terry J,
Badalian-Very G, Rollins BJ, Fleck P, Aslam M and Degar BA: BRAF
V600E-Positive multisite Langerhans cell histiocytosis in a preterm
neonate. AJP Rep. 3:63–66. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yousem SA, Dacic S, Nikiforov YE and
Nikiforova M: Pulmonary Langerhans cell histiocytosis: Profiling of
multifocal tumors using next-generation sequencing identifies
concordant occurrence of BRAF V600E mutations. Chest.
143:1679–1684. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chilosi M, Facchetti F, Caliò A, Zamò A,
Brunelli M, Martignoni G, Rossi A, Montagna L, Piccoli P, Dubini A,
et al: Oncogene-induced senescence distinguishes indolent from
aggressive forms of pulmonary and non-pulmonary Langerhans cell
histiocytosis. Leuk Lymphoma. 55:2620–2626. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Haroche J, Charlotte F, Arnaud L, von
Deimling A, Hélias-Rodzewicz Z, Hervier B, Cohen-Aubart F, Launay
D, Lesot A, Mokhtari K, et al: High prevalence of BRAF V600E
mutations in Erdheim-Chester disease but not in other
non-Langerhans cell histiocytoses. Blood. 120:2700–2703. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wei R, Wang Z, Li X, Shu Y and Fu B:
Frequent BRAFV600E mutation has no effect on tumor invasiveness in
patients with Langerhans cell histiocytosis. Biomed Rep. 1:365–368.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Berres ML, Lim KP, Peters T, Price J,
Takizawa H, Salmon H, Idoyaga J, Ruzo A, Lupo PJ, Hicks MJ, et al:
BRAF-V600E expression in precursor versus differentiated dendritic
cells defines clinically distinct LCH risk groups. J Exp Med.
211:669–683. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Héritier S, Emile JF, Barkaoui MA, Thomas
C, Fraitag S, Boudjemaa S, Renaud F, Moreau A, Peuchmaur M,
Chassagne-Clément C, et al: BRAF mutation correlates with high-risk
Langerhans cell histiocytosis and increased resistance to
first-line therapy. J Clin Oncol. 34:3023–3030. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tiacci E, Trifonov V, Schiavoni G, Holmes
A, Kern W, Martelli MP, Pucciarini A, Bigerna B, Pacini R, Wells
VA, et al: BRAF mutations in hairy-cell leukemia. N Engl J Med.
364:2305–2315. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Davidsson J, Lilljebjörn H, Panagopoulos
I, Fioretos T and Johansson B: BRAF mutations are very rare in B-
and T-cell pediatric acute lymphoblastic leukemias. Leukemia.
22:1619–1621. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Maevis V, Mey U, Schmidt-Wolf G and
Schmidt-Wolf IG: Hairy cell leukemia: Short review, today's
recommendations and outlook. Blood Cancer J. 4:e1842014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tadmor T, Tiacci E, Falini B and Polliack
A: The BRAF-V600E mutation in hematological malignancies: A new
player in hairy cell leukemia and Langerhans cell histiocytosis.
Leuk Lymphoma. 53:2339–2340. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Trifa AP, Popp RA, Cucuianu A, Coadă CA,
Urian LG, Militaru MS, Bănescu C, Dima D, Farcaş MF, Crişan TO, et
al: Absence of BRAF V600E mutation in a cohort of 402 patients with
various chronic and acute myeloid neoplasms. Leuk Lymphoma.
53:2496–2497. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dietrich S, Hüllein J, Hundemer M, Lehners
N, Jethwa A, Capper D, Acker T, Garvalov BK, Andrulis M, Blume C,
et al: Continued response off treatment after BRAF inhibition in
refractory hairy cell leukemia. J Clin Oncol. 31:e300–e303. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chapman PB, Hauschild A, Robert C, Haanen
JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et
al: Improved survival with vemurafenib in melanoma with BRAF V600E
mutation. N Engl J Med. 364:2507–2516. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kainthla R, Kim KB and Falchook GS:
Dabrafenib for treatment of BRAF-mutant melanoma. Pharmgenomics
Pers Med. 7:21–29. 2013.PubMed/NCBI
|
|
35
|
Sullivan RJ and Flaherty KT: Resistance to
BRAF-targeted therapy in melanoma. Eur J Cancer. 49:1297–1304.
2013. View Article : Google Scholar : PubMed/NCBI
|
